EMA approves new antimalarial drug developed by Shinpoong

Shinpoong Pharmaceutical Co. said Monday that the European Medicines Agency (EMA) approved a new artemisinin based combination therapy (ACT) Pyramax for treatment of malaria.

Co-developed by Switzerland based Medicines for Malaria Venture (MMV) and Shipoong, Pyramax is a fixed-dose combination of pyronaridine and artesunate that has completed a program of clinical trials demonstrating more t...